Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Bulk RNA sequencing data of AB1-HA murine mesothelioma tumors from mice treated with tretinoin and immune checkpoint therapy

ABSTRACT: Bulk RNA sequencing data of AB1-HA murine mesothelioma tumors from mice treated with tretinoin and immune checkpoint therapy

PROVIDER: PRJNA772938 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

Bulk RNA sequencing data of AB1-HA murine mesothelioma tumors from mice treated with tretinoin and immune checkpoint therapy

Project description:Bulk RNA sequencing data of AB1-HA murine mesothelioma tumors from mice treated with tretinoin, immune checkpoint therapy or the combination of tretinoin+immune checkpoint therapy.

2022-03-17 | GSE186195 | GEO

Bulk RNAseq of AB1-HA murine mesothelioma tumors from complete responders and partial responders to cyclophosphamide chemotherapy

Project description:Purpose: To compare the gene expression profiles of tumors from complete responders and partial responders to cyclophosphamide chemotherapy. AB1-HA murine mesothelioma tumors were excised one day prior to cyclophosphamide or three or seven days post cyclophosphamide.

2022-08-18 | GSE182674 | GEO

Genexpression of murine mesothelioma cell lines AC29 and AB1

Project description:RNA from two murine mesothelioma cell lines (AC29 and AB1) was extracted and hybridized to Affymetrix Microarrays to compare gene expression. Both mesothelioma cell lines were established following intraperitoneal introduction of crocidolite (asbestos) fibers (Davis et al. 1992) in CBA mice (AC29 cell line), and BALB/c mice (AB1).

2017-03-29 | GSE97150 | GEO

Bulk RNAseq of AB1-HA murine mesothelioma tumors from immunocompetent or CD4+ T cell depleted mice.

Project description:Bulk RNAseq of AB1-HA murine mesothelioma tumors from immunocompetent or CD4+ T cell depleted mice.

| PRJNA756568 | ENA

Bulk RNAseq of AB1-HA murine mesothelioma tumors from complete responders and partial responders to cyclophosphamide chemotherapy

Project description:Bulk RNAseq of AB1-HA murine mesothelioma tumors from complete responders and partial responders to cyclophosphamide chemotherapy

| PRJNA757407 | ENA

Gene expression patterns in responding versus non-responding AB1-HA tumors from mice during immunotherapy

2015-07-22 | GSE63557 | GEO

Gene expression patterns in responding versus non-responding AB1-HA tumors from mice during immunotherapy

Project description:Balb/c mice were inoculated subcutaneously with AB1-HA cells on both flanks on day 0. The mice were then treated with anti-CTLA-4 on day 5 or 6. 7 days later, one tumor was removed for gene expression studies, and the other was left in situ to monitor tumor growth and determine if the eventual outcome was progression or regression. The study design consisted of three experimental groups; (i) untreated mice; (ii) anti-CTLA-4 treated responders; (iii) anti-CTLA-4 treated nonresponders. There were 10 animals in each group.

2015-07-22 | E-GEOD-63557 | biostudies-arrayexpress

Gene expression profile at single cell level of CD45+ cells from AB1 mesothelioma treated with either vaccinia virus Tiantan strain or mock-treated

Project description:To understand the immune infiltrates in the tumor microenvironment in response to vaccinia virotherapy, we used single cell RNA sequencing (scRNAseq) to analyze the diversity of total CD45+ isolated from AB1 mesothelioma

2023-12-01 | GSE221653 | GEO

Time-course bulk RNAseq and single-cell RNAseq of murine AB1 mesothelioma and Renca renal cancer following immune checkpoint therapy

Project description:Time-course bulk RNAseq and single-cell RNAseq of murine AB1 mesothelioma and Renca renal cancer following immune checkpoint therapy

| PRJNA880346 | ENA

Time-course bulk RNAseq and single-cell RNAseq of murine AB1 mesothelioma and Renca renal cancer following immune checkpoint therapy

Project description:The on/off dynamics of IFNβ signalling underlie the therapeutic response to immune checkpoint therapy in cancer in mice

2022-09-14 | GSE213296 | GEO